Children’s sacral PEMF vs sham: less leakage at three months
Q: Did sacral PEMF reduce leakage more than sham after three months?
Related: what is pulsed electromagnetic field therapy (KYMA369)
A: Yes—in a 2026 randomized trial of 40 children with myelomeningocele and overactive bladder, adding sacral pulsed electromagnetic stimulation to the same medicine reduced daily incontinence scores more than sham after three months. Twelve of 20 children in the active group were dry, compared with four of 20 in the sham group.
Who took part in the three-month comparison?
Forty children aged four to twelve took part at Cairo University’s outpatient physical therapy clinic. All had myelomeningocele, a form of spina bifida, and a neurogenic overactive bladder. They were randomly assigned to two groups of 20, and all completed the study.
Both groups continued the same anticholinergic medicine, oxybutynin. One received active stimulation; the other received sham sessions. The study tested an addition to usual medical care, not a replacement for it.
What happened during each session?
Children lay face down while an applicator delivered stimulation without skin contact over the sacral region at the base of the spine, S2–S4. The trial device was PMT Qs by ASALASER, set to 5 Hz. Each visit lasted 20 minutes, three times a week for three consecutive months. The sham group followed the same schedule without active stimulation.
This was a supervised clinic procedure. The library card below records the reported frequency and session length for readers interested in the study’s settings; it does not reproduce the device’s magnetic output.
How much did leakage and bladder capacity change?
At three months, the median daily incontinence score was 0 in the active group and 2 in the sham group, a statistically significant difference (P=0.001). Twelve children receiving active stimulation were entirely dry, compared with four receiving sham.
Maximum bladder capacity measured during testing averaged 195.7 mL after active stimulation and 172.4 mL after sham (P=0.048). The volume at the first involuntary bladder contraction was also higher with active stimulation: 143.9 mL versus 125.5 mL.
Both groups improved from their starting measurements. The important comparison is the additional improvement with active stimulation alongside the same medicine.
What should families and clinicians keep in mind?
This was a small, single-center, single-blind study. It measured results after three months, so it cannot tell us how long any benefit lasts. These children had a specific neurological condition; the findings do not establish the same result for ordinary adult urgency or age-related leakage.
The researchers also reported higher detrusor leak point pressure with active stimulation. Bladder pressure needs specialist interpretation in myelomeningocele, where protecting the kidneys matters as much as achieving dryness; a higher pressure is not automatically a better result. The study did not establish long-term kidney protection.
No side effects were reported during the study, but 40 children are not enough to rule out uncommon problems. A pediatric urology team should guide decisions about care.
| Result | What the paper reported |
|---|---|
| Entirely dry after three months | 12 of 20 children with active stimulation; 4 of 20 with sham. Both groups received the same medicine. |
| Daily incontinence score | Post-treatment median 0 with active stimulation versus 2 with sham; between-group P=0.001. |
| Maximum bladder capacity | Post-treatment mean 195.7 mL with active stimulation versus 172.4 mL with sham; P=0.048. |
| Follow-up and safety | All 40 children completed the study; no side effects were reported. Outcomes beyond three months were not established. |
Related tones in the KYMA library
The first card preserves the study’s 5 Hz setting and 20-minute session length. Incontinence is a separate library set matching the measured outcome; the trial did not test that set. A playback frequency does not reproduce the clinical applicator’s magnetic field. For an adult personal listening session, open a card in the app and use comfortable headphone volume. This pediatric medical intervention belongs with the child’s specialist team.
Frequency and session length reported for supervised sacral electromagnetic stimulation in a randomized pediatric bladder trial. The tone carries the frequency number, not the clinical device’s field strength or treatment delivery. · 20 minutes
CAFL · 5 minutes
Frequently asked questions
Which frequency and session length did the trial use?
The Sacral bladder trial setting — 5 Hz card records 5 Hz and 20 minutes, the settings reported for the supervised clinic sessions. Incontinence is the outcome-matching library set alongside it, but it was not tested in this trial. The frequency card does not carry the applicator’s field strength, and headphone playback is not the same intervention.
Did the children stop their bladder medicine?
No. Both groups continued oxybutynin. The comparison was active stimulation plus medicine versus sham stimulation plus the same medicine.
Does this show the same benefit for adult bladder leakage?
The study concerned children aged four to twelve with myelomeningocele and neurogenic overactive bladder. It does not establish the same benefit for adults with other causes of leakage.
Were the children followed beyond three months?
The reported comparison was at three months. The study does not establish whether the improvements persist after that period.
Original research
Heba A. Khalifa and colleagues. Electromagnetic stimulation for overactive bladder in myelomeningocele children: randomized controlled trial. European Journal of Physical and Rehabilitation Medicine, published July 3, 2026. The full paper is freely available.
KYMA is working to establish a science-based podcast, because reliable information about this topic is almost impossible to find on ordinary social media.